Prostate Cancer - Results from #240

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma. September 16, 2024

Targeted Prostate Biopsy: How, When, and Why? A Systematic Review. September 16, 2024

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. September 16, 2024

Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308. September 14, 2024

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. September 14, 2024

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer. September 14, 2024

Association of Baseline Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC) September 13, 2024

SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort September 13, 2024

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. September 13, 2024

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. September 13, 2024

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance. September 13, 2024

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. September 13, 2024

Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort. September 13, 2024

Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy. September 13, 2024

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. September 13, 2024

YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. September 13, 2024

PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. September 13, 2024

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. September 13, 2024

Safety and feasibility of "three arms settings" robot-assisted radical prostatectomy using the Hugo RAS system: surgical set-up in a double-center large case series. September 12, 2024

Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study. September 12, 2024

Page 13 of 1434